Jasper Therapeutics Reported FY23 EPS Loss of $(1.50), Cash Balance of $86.9M
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics reported its fiscal year 2023 financial results, including a net loss of $64.5 million, or $6.18 per share, and a cash balance of $86.9 million. Research and development expenses were $51.8 million, while general and administrative expenses totaled $17.1 million.
March 04, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Jasper Therapeutics reported a significant net loss of $64.5 million for FY23, with a cash balance of $86.9 million. R&D and G&A expenses were substantial contributors to the loss.
The reported net loss and the details on expenses indicate financial strain, which could negatively impact investor sentiment and the stock price in the short term. The substantial cash balance may provide some cushion, but the high expenses and net loss are likely to be the focal points for investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100